Endocyte Given Average Recommendation of “Buy” by Analysts (NASDAQ:ECYT)
Endocyte (NASDAQ:ECYT) has received a consensus rating of “Buy” from the ten ratings firms that are currently covering the stock, American Banking and Market News reports. Three research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $26.17.
Several analysts have recently commented on the stock. Analysts at Chardan Capital reiterated a “buy” rating on shares of Endocyte in a research note on Wednesday, July 30th. Separately, analysts at Brean Capital initiated coverage on shares of Endocyte in a research note on Tuesday, July 8th. They set a “buy” rating and a $22.00 price target on the stock.
Endocyte (NASDAQ:ECYT) traded down 3.40% on Thursday, hitting $6.26. 209,178 shares of the company’s stock traded hands. Endocyte has a 1-year low of $5.91 and a 1-year high of $33.70. The stock’s 50-day moving average is $6.46 and its 200-day moving average is $11.29. The company has a market cap of $260.1 million and a price-to-earnings ratio of 18.62.
Endocyte (NASDAQ:ECYT) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.52 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.10 by $0.42. The company had revenue of $49.17 million for the quarter, compared to the consensus estimate of $26.62 million. Endocyte’s revenue was up 198.4% compared to the same quarter last year. Analysts expect that Endocyte will post $-0.08 EPS for the current fiscal year.
Endocyte, Inc (NASDAQ:ECYT) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.